Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical has received Medical Device Regulation (MDR) certification from the EU, lifting post-market restrictions on its pancreatic cancer treatment device, OncoSil™. This approval is expected to streamline operations, reduce costs, and enhance market access in the EU and UK, potentially boosting the company’s commercial success and allowing for a resubmission of their application to the Australian market.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a company specializing in the development of cancer treatment devices, particularly the OncoSil™ brachytherapy device for treating locally advanced unresectable pancreatic cancer. This device is designed to deliver targeted radioactive treatment directly to pancreatic tumors, often in combination with chemotherapy, and has been approved for use in over 30 countries including the European Union and the United Kingdom.
Average Trading Volume: 21,946,210
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$23.03M
See more insights into OSL stock on TipRanks’ Stock Analysis page.
